Stay updated on Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page
- CheckyesterdayChange DetectedRevision updated from v3.4.2 to v3.4.3 in the page history.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedA new revision v3.4.2 was added to the history, replacing the previous v3.4.1.SummaryDifference0.1%

- Check30 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 in the page history; no visible changes to study details or content.SummaryDifference0.1%

- Check52 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 from the page's revision history.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision: v3.3.3 has been added to the history, and HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed from the page footer. These updates reflect minor metadata changes to the page's revision history.SummaryDifference0.1%

- Check103 days agoChange DetectedRevision: v3.3.2 appears as the site revision tag, replacing v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.